Unfulfilled potential: Using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis

Bulletin of the World Health Organization

Volumn 85, Issue 7, 2007, Pages 545-549

  Lammie, Patrick ^a   Milner, Trevor ^b   Houston, Robin ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b PAN AMERICAN HEALTH ORGANIZATION   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLCARBAMAZINE; DRUG VEHICLE; IODINE; SODIUM CHLORIDE;

DRUG USER; FILARIASIS; IODINE; ORGANIC SALT;

CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FILARIASIS; GUYANA; HUMAN; IODINATION; IODINE DEFICIENCY; MICROFILARIASIS; REVIEW; TABLET; UNSPECIFIED SIDE EFFECT;

DIETHYLCARBAMAZINE; ELEPHANTIASIS, FILARIAL; FILARICIDES; GUYANA; HUMANS; IODINE; PUBLIC HEALTH PRACTICE; SODIUM CHLORIDE, DIETARY;

ASIA; CHINA; EURASIA; FAR EAST;

EID: 34447274976     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.06.034108     Document Type: Review

References (44)

1. Michael E, Bundy DA, Grenfell BT. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology 1996;112:409-28.
2. The World Health Report 1995 - bridging the gaps. World Health Forum 1995;16:377-85.
3. Weil GJ, Lammie PJ, Weiss N. The ICT filariasis test: a rapid format antigen test for diagnosis of bancroftian filariasis. Parasitol Today 1997;13:401-4.
4. Gyapong JO, Kyelem D, Kleinschmidt I, Agbo K, Ahouandogbo F, Gaba J, et al. The use of spatial analysis in mapping the distribution of bancroftian filariasis in four West African countries. Ann Trop Med Parasitol 2002;96:695-705.
5. Ottesen EA, Duke BOL, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariaisis. Bull World Health Organ 1997;75:491-503.
6. Global Programme to Eliminate Lymphatic Filariasis. Wkly Epidemiol Rec 2006;81:221-32.
7. Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 countries of the Global Programme to Eliminate Lymphatic Filariasis. Wkly Epidemiol Rec 2004;79:358-65.
8. de Rochars MB, Direny AN, Roberts JM, Addiss DG, Radday J, Beach MJ, et al. Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs. Am J Trop Med Hyg 2004;71:466-70.
9. Molyneux DH, Hotez PJ, Fenwick A. "Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2005;2:e336.
10. McLaughlin SI, Radday J, Michel MC, Addiss DG, Beach MJ, Lammie PJ, et al. Frequency, severity and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole, Leogane, Haiti, 2000. Am J Trop Med Hyg 2003;68:568-73.
11. Babu BV, Kar SK. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 2004;9:702-9.
12. Meyrowitsch DW, Simonsen PE. Long-term effect of mass diethylcarbamazine chemotherapy on bancroftian filariasis, results at four years after the start of treatment. Trans R Soc Trop Med Hyg 1998;92:98-103.
13. Freeman AR, Lammie PJ, Houston R, Lapointe MD, Streit TG, Jooste PL, et al. A community-based trial for the control of lymphatic filariasis and iodine deficiency using salt fortified with diethylcarbamazine and iodine. Am J Trop Med Hyg 2001;65:865-71.
14. Michael E, Meyrowitsch DW, Simonsen PE. Cost and cost effectiveness of mass diethylcarbamazine chemotherapy for the control of bancroftian filariasis: comparison of four strategies in Tanzania. Trop Med Int Health 1996;1:414-26.
15. Gelband H. Diethylcarbamazine salt in the control of lymphatic filariasis. Am J Trop Med Hyg 1994;50:655-62.
16. Houston R. Salt fortified with diethylcarbamazine (DEC) as an effective intervention for lymphatic filariasis, with lessons learned from salt iodization programmes. Parasitology 2000;121 (Suppl):S161-73.
17. Control of lymphatic filariasis in China. Geneva: WHO; 2003.
18. Liu J, Chen Z, Huang X, Tu Z. Mass treatment of filariasis using DEC-medicated salt. J Trop Med Hyg 1992;95:132-5.
19. Delange F, de Benoist B, Pretell E, Dunn JT. Iodine deficiency in the world: where do we stand at the turn of the century? Thyroid 2001;11:437-47.
20. Andersson M, Takkouche B, Egli I, Allen HE, de Benoist B. Current global iodine status and progress over the last decade toward the elimination of iodine deficiency. Bull World Health Organ 2005;83:518-25.
21. Pretell EA, Delange F, Hostalek U, Corigliano S, Barreda L, Higa AM, et al. Iodine nutrition improves in Latin America. Thyroid 2004;14:590-9.
22. Hawking F, Marques RJ. Control of bancroftian filariasis by cooking salt medicated with diethylcarbamazine. Bull World Health Organ 1967;37:405-14.
23. Kaul SM, Raina VK, Joshi RD, Sayed Mohamad Koya CN, Kumar A, Verghese T. Efficacy of diethylcarbamazine medicated salt in interrupting Brugia malayi transmission in hill tribe settlements in Kerala State. J Commun Dis 1992;24:16-9.
24. Krishnarao P, Raminder K, Ghosh TK. Long-term effect of diethylcarbamazine medicated common salt on Bancroftian filariasis. J Commun Dis 1991;23:128-30.
25. Meyrowitsch DW, Simonsen PE, Makunde WH. Mass diethylcarbamazine chemotherapy for control of bancroftian filariasis through community participation: comparative efficacy of a low monthly dose and medicated salt. Trans R Soc Trop Med Hyg 1996;90:74-9.
26. Meyrowitsch DW, Simonsen PE, Makunde WH. Mass DEC chemotherapy for control of bancroftian filariasis: comparative efficacy of four strategies two years after start of treatment. Trans R Soc Trop Med Hyg 1996;90:423-8.
27. Fan PC. Eradication of bancroftian filariasis by diethylcarbamazine- medicated common salt on Little Kinmen (Liehyu district), Kinmen (Quemoy) Islands. Ann Trop Med Parasitol 1990;84:25-33.
28. Fan PC. Filariasis eradication on Kinmen Proper, Kinmen (Quemoy) Islands. Acta Trop 1990;47:161-9.
29. Reddy GS, Venkateswaralu N. Mass administration of DEC-medicated salt for filariasis control in the endemic populaition of Karaikal, south India: implementation and impact assessment. Bull World Health Organ 1996;74:85-90.
30. Narasimham MV, Sharma SP, Sundaram RM, Reddy GS, Raina VK, Sambasivam V, et al. Control of bancroftian filariasis by diethylcarbamazine medicated common salt in Karaikal, Pondicherry, India. J Commun Dis 1989;21:157-70.
31. Shenoy RK, Varghese J, Kuttikkal VV, Kumaraswami V. The efficacy, tolerability and safety of diethylcarbamazine-fortified salt in the treatment of the microfilaraemias of brugian filariasis: an open hospital-based study. Ann Trop Med Parasitol 1998;92:285-93.
32. Dadzie KY, Bird AC, Awadzi K, Schulz-Key H, Gilles HM, Aziz MA. Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis. Br J Ophthalmol 1987;71:78-85.
33. Awadzi K, Gilles HM. Diethylcarbamazine in the treatment of patients with onchocerciasis. Br J Clin Pharmacol 1992;34:281-8.
34. Meyrowitsch DW, Simonsen PE, Magnussen P. Tolerance to diethylcarbamazine-medicated salt in individuals infected with Onchocerca volvulus. Trans R Soc Trop Med Hyg 2000;94:444-8.
35. Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis 2003;188:1371-81.
36. Michael E, Malecela-Lazaro MN, Simonsen PE, Pedersen EM, Barker G, Kumar A, et al. Mathematical modeling and the control of lymphatic filariasis. Lancet Infect Dis 2004;4:223-33.
37. Nutman TB, Miller KD, Mulligan M, Reinhardt GN, Currie BJ, Steel C, et al. Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind study. N Engl J Med 1988;319:752-6.
38. Nelson CT, McCall JW, Rubin SB, Buzhardt LF, Dorion DW, Graham W, et al. 2005 guidelines for the diagnosis, prevention and management of heartworm (Dirofilaria immitis) infection in dogs. Vet Parasitol 2005;133:255-66.
39. Ramzy RM, Goldman AS, Kamal HA. Defining the cost of the Egyptian lymphatic filariasis elimination programme. Filaria J 2005;4:7.
40. de Rochars MB, Kanjilal S, Direny AN, Radday J, Lafontant JG, Mathieu E, et al. The Leogane, Haiti, demonstration project: decreased microfilaremia and program costs after three years of mass drug administration. Am J Trop Med Hyg 2005;73:888-94.
41. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 2006;367:1193-208.
42. Malecela-Lazaro M, Twum-Danso N. Towards a strategic plan for research to support the global program to eliminate lymphatic filariasis. 2.4 Program implementation. Am J Trop Med Hyg 2004;71 Suppl:S16-9.
43. Hoerauf A. New strategies to combat filariasis. Expert Rev Anti Infect Ther 2006;4:211-22.
44. Technical Advisory Group of the Global Alliance to Eliminate Lymphatic Filariasis. DEC fortified salt for the elimination of lymphatic filariasis: a manual for program managers, 2004. Available at: http://www.taskforce.org/ LFSC/saltmanual.pdf